Alessio Cortellini: Immune-suppressive role of RANKL in patients with NSCLC treated with ICI

Alessio Cortellini, Assistant Professor at Campus Bio-Medico University of Rome, shared a post by Journal for ImmunoTherapy of Cancer, on X:

“Happy to share this work out on Journal for ImmunoTherapy of Cancer on the potential immune-suppressive role of RANKL in patients with NSCLC treated with ICI. Entirely thought through and performed at UCBM.”.

Quoting Journal for ImmunoTherapy of Cancer‘s post:

“New JITC article: Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).”

Read further.
Source: Alessio Cortellini/X and Journal for ImmunoTherapy of Cancer/X